Chapman Financial Group’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$369K Sell
2,355
-282
-11% -$42.3K 0.25% 91
2026
Q1
$403K Sell
2,637
-612
-19% -$93.8K 0.29% 86
2025
Q4
$448K Sell
3,249
-23
-0.7% -$3.01K 0.31% 86
2025
Q3
$420K Hold
3,272
0.29% 89
2025
Q2
$396K Buy
+3,272
New +$369K 0.34% 75
2024
Q4
$363K Buy
+3,733
New +$398K 0.29% 83

Other funds holding NVS

Chapman Financial Group's NVS Position: Q2 2026 in Review

Chapman Financial Group reduced its Novartis (NVS) stake by 11% in Q2 2026, selling an estimated $42.3K and leaving 2,355 shares worth $369K. The position accounts for 0.25% of the portfolio, ranked #91.

Chapman Financial Group first reported a position in NVS in Q4 2024 and has held it in 6 quarters since. The position peaked at $448K in Q4 2025. 1,620 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Chapman Financial Group held 2,355 shares of Novartis worth $369K as of Q2 2026.
  • Chapman Financial Group sold 282 Novartis shares in Q2 2026, an estimated $42.3K.
  • Novartis made up 0.25% of Chapman Financial Group's portfolio in Q2 2026, its #91 holding.
  • Chapman Financial Group first reported a position in Novartis in Q4 2024 and has held it in 6 quarters since.
  • Chapman Financial Group's Novartis position peaked at $448K in Q4 2025.
  • 1,620 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Chapman Financial Group's 13F filing for Q2 2026, filed 5 Aug 2026.